Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment

Bispecific T‐cell Engagers (BiTE®) antibody constructs enable a polyclonal T‐cell response to cell‐surface tumor‐associated antigens, bypassing the narrow specificities of T‐cell receptors and the need for antigen presentation through the major histocompatibility complex pathways. Blinatumomab, a CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuraszeck, T, Kasichayanula, S, Benjamin, JE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
State of the Art
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763312/
https://www.ncbi.nlm.nih.gov/pubmed/28182247
http://dx.doi.org/10.1002/cpt.651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763312/
https://www.ncbi.nlm.nih.gov/pubmed/28182247
http://dx.doi.org/10.1002/cpt.651

Ejemplares similares